References
- Linaker OM, Thoresen R, Figenschou L, Solvberg H, Refsnes U, Jakobsen D. Norske psykiatriske sikkerhetsenheter. Pasienter og virksomhet. Tidsskr Nor Lægeforen 1994; 114: 1520–3
- Rasmussen K, Levander S. Symptoms and personality characteristics of patients in a maximum security unit. Int J Law Psychiatry 1996; 19: 27–37
- Walsh E, Leese M, Taylor P, Johnston I, Burns T, Creed F, et al. Psychosis in high-security and general psychiatric services: Report from the UK700 and Special Hospitals Treatment Resistant Schizophrenia groups. Br J Psychiatry 2002; 180: 351–7
- Harty M-A, Shaw J, Thomas S, Dolan M, Davies L, Thornicroft G, et al. The security, clinical and social needs of patients in high security psychiatric hospitals in England. J Forensic Psychiatry Psychol 2004; 15: 208–21
- Rasmussen K, Levander S. Schizophrenia and violence. Tidsskr Nor Lægeforen 2002; 122: 2303–5
- Norwegian Board of Health (Helsetilsynet). Schizofreni: kliniske retningslinjer for utredning og behandling. In: Statens helsetilsyns utredningsserie; 2000:9. Helsetilsynet, Pb. 8128 Dep, 0032 Oslo, Norway. www.helsetilsynet.no.
- American Psychiatric Association (APA). Treatment Recommendations for patients with schizophrenia, Part A. Am J Psychiatry 2004;161. Suppl 2:1–56.
- Tavernor R, Swinton M, Tavernor S. High-dose antipsychotic medication in maximum security. J Forensic Psychiatry 2000; 11: 36–48
- Bains-Jatinder JS, Nielssen OB. Combining depot antipsychotics with novel antipsychotics in forensic patients. Psychiatr Bull 2003; 27: 14–16
- Brown CS, Lloyd KR, Donovan M. Trends in admissions to a regional secure unit (1983–1997). Med Sci Law 2001; 41: 35–40
- Butwell M, Jamieson E, Leese M, Taylor P. Trends in special (high-security) hospitals. 2: Residency and discharge episodes 1986–1995. Br J Psychiatry 2000; 176: 260–5
- Norwegian Pharmaceutical Product Compendium (Felleskatalogen) 2004. 46. utgave. Felleskatalogen AS, Pb. 204 sentrum, 0103 Oslo, Norway. www.felleskatalogen.no.
- Stubbs JH, Haw CM. Medication. schizophrenia and the forensic multidisciplinary team. Br J Forensic Practice 2001; 3: 29–33
- Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren J, Salavtore P, et al. Inpatient antipsychotic drug use in 1998, 1993 and 1989. Am J Psychiatry 2002; 159: 1932–4
- Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 1996; 23: 983–5
- Zanger UM, Raimondo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics. biochemistry. Arch Pharmacol 2004; 369: 23–37
- Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized patients: Case–control study of risks versus benefits. Am J Psychiatry 2004; 161: 700–6
- Leong G-B, Silva JA. Neuroleptic induced akathisia and violence: A review. J Forensic Sci 2003; 48: 187–9
- Krakowski M-I, Kunz M, Czobor P, Volavka J. Long-term high-dose neuroleptic treatment: Who gets it and why?. Hosp Community Psychiatry 1993; 44: 640–4
- Scheller-Gilkey G, Wooline BJ, Cooper I, Gay O, Moynes KA, Miller AH. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Alcohol Abuse 2003; 29: 553–66
- Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I. First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr Res 2004; 66: 125–35
- Diaz F, de-Leon J. J Clin Psychiatry. Excessive antipsychotic dosing in 2 U.S. state hospitals 2002; 63: 998–1003